Literature DB >> 27338091

Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.

Suchismita Mohanty1, Atish Mohanty1, Natalie Sandoval1, Thai Tran2, Victoria Bedell3, Jun Wu4, Anna Scuto3, Joyce Murata-Collins3, Dennis D Weisenburger3, Vu N Ngo1.   

Abstract

Elevated cyclin D1 (CCND1) expression levels in mantle cell lymphoma (MCL) are associated with aggressive clinical manifestations related to chemoresistance, but little is known about how this important proto-oncogene contributes to the resistance of MCL. Here, we showed that RNA interference-mediated depletion of CCND1 increased caspase-3 activities and induced apoptosis in the human MCL lines UPN-1 and JEKO-1. In vitro and xenotransplant studies revealed that the toxic effect of CCND1 depletion in MCL cells was likely due to increase in histone H2AX phosphorylation, a DNA damage marker. DNA fiber analysis suggested deregulated replication initiation after CCND1 depletion as a potential cause of DNA damage. Finally, in contrast to depletion or inhibition of cyclin-dependent kinase 4, CCND1 depletion increased chemosensitivity of MCL cells to replication inhibitors hydroxyurea and cytarabine. Our findings have an important implication for CCND1 as a potential therapeutic target in MCL patients who are refractory to standard chemotherapy.

Entities:  

Keywords:  Chemoresistance; DNA damage; cyclin D1; mantle cell lymphoma; replication stress

Mesh:

Substances:

Year:  2016        PMID: 27338091      PMCID: PMC5674995          DOI: 10.1080/10428194.2016.1198958

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  37 in total

1.  Characterization of 4 mantle cell lymphoma cell lines.

Authors:  Hesham M Amin; Timothy J McDonnell; L Jeffrey Medeiros; Georgios Z Rassidakis; Vasiliki Leventaki; Sean L O'Connor; Michael J Keating; Raymond Lai
Journal:  Arch Pathol Lab Med       Date:  2003-04       Impact factor: 5.534

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Authors:  John P Leonard; Ann S LaCasce; Mitchell R Smith; Ariela Noy; Lucian R Chirieac; Scott J Rodig; Jian Q Yu; Shankar Vallabhajosula; Heiko Schoder; Patricia English; Donna S Neuberg; Peter Martin; Michael M Millenson; Scott A Ely; Rachel Courtney; Naveed Shaik; Keith D Wilner; Sophia Randolph; Annick D Van den Abbeele; Selina Y Chen-Kiang; Jeffrey T Yap; Geoffrey I Shapiro
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

4.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

5.  Cyclin D1 predicts the prognosis of advanced serous ovarian cancer.

Authors:  Tomoko Hashimoto; Nozomu Yanaihara; Aikou Okamoto; Takashi Nikaido; Misato Saito; Satoshi Takakura; Makoto Yasuda; Hiroshi Sasaki; Kazunori Ochiai; Tadao Tanaka
Journal:  Exp Ther Med       Date:  2011-01-18       Impact factor: 2.447

6.  Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.

Authors:  Eva Petermann; Manuel Luís Orta; Natalia Issaeva; Niklas Schultz; Thomas Helleday
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

7.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Authors:  Thomas S Lin; Kristie A Blum; Diane Beth Fischer; Sarah M Mitchell; Amy S Ruppert; Pierluigi Porcu; Eric H Kraut; Robert A Baiocchi; Mollie E Moran; Amy J Johnson; Larry J Schaaf; Michael R Grever; John C Byrd
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  C Tom Kouroukis; Andrew Belch; Michael Crump; Elizabeth Eisenhauer; Randy D Gascoyne; Ralph Meyer; Reinhard Lohmann; Pedro Lopez; Jean Powers; Robert Turner; Joseph M Connors
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

9.  Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model.

Authors:  R M'kacher; F Farace; A Bennaceur-Griscelli; D Violot; B Clausse; J Dossou; A Valent; C Parmentier; V Ribrag; J Bosq; P Carde; A G Turhan; A Bernheim
Journal:  Cancer Genet Cytogenet       Date:  2003-05

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

View more
  7 in total

1.  Ginger extract adjuvant to doxorubicin in mammary carcinoma: study of some molecular mechanisms.

Authors:  Nahla E El-Ashmawy; Naglaa F Khedr; Hoda A El-Bahrawy; Hend E Abo Mansour
Journal:  Eur J Nutr       Date:  2017-02-22       Impact factor: 5.614

2.  Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.

Authors:  Pratikkumar H Vekaria; Amar Kumar; Dharmalingam Subramaniam; Neil Dunavin; Anusha Vallurupalli; Frank Schoenen; Siddhartha Ganguly; Shrikant Anant; Joseph P McGuirk; Roy A Jensen; Rekha Rao
Journal:  Leukemia       Date:  2019-01-21       Impact factor: 11.528

3.  KIF15 is involved in development and progression of Burkitt lymphoma.

Authors:  Zhao Wang; Meiting Chen; Xiaojie Fang; Huangming Hong; Yuyi Yao; He Huang
Journal:  Cancer Cell Int       Date:  2021-05-13       Impact factor: 5.722

4.  Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

Authors:  Atish Mohanty; Natalie Sandoval; An Phan; Thang V Nguyen; Robert W Chen; Elizabeth Budde; Matthew Mei; Leslie Popplewell; Lan V Pham; Larry W Kwak; Dennis D Weisenburger; Steven T Rosen; Wing C Chan; Markus Müschen; Vu N Ngo
Journal:  Blood       Date:  2018-12-10       Impact factor: 25.476

5.  shRNA-induced silencing of Ras-related C3 botulinum toxin substrate 1 inhibits the proliferation of colon cancer cells through upregulation of BAD and downregulation of cyclin D1.

Authors:  You-Sheng Huang; Na Jie; Yi-Xin Zhang; Ke-Jian Zou; Yang Weng
Journal:  Int J Mol Med       Date:  2017-12-22       Impact factor: 4.101

6.  CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.

Authors:  Atish Mohanty; Natalie Sandoval; Manasi Das; Raju Pillai; Lu Chen; Robert W Chen; Hesham M Amin; Michael Wang; Guido Marcucci; Dennis D Weisenburger; Steven T Rosen; Lan V Pham; Vu N Ngo
Journal:  Oncotarget       Date:  2016-11-08

7.  Ribosomal protein uL3 targets E2F1 and Cyclin D1 in cancer cell response to nucleolar stress.

Authors:  Annalisa Pecoraro; Pietro Carotenuto; Giulia Russo; Annapina Russo
Journal:  Sci Rep       Date:  2019-10-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.